100 related articles for article (PubMed ID: 25591760)
1. The OPN gene polymorphism confers the susceptibility and response to Ara-C based chemotherapy in Chinese AML patients.
Zhang R; Yang W; Li YC; Zhang GJ; Yao K; Hu R; Wu B
Cell Physiol Biochem; 2015; 35(1):175-83. PubMed ID: 25591760
[TBL] [Abstract][Full Text] [Related]
2. Polymorphism -433 C>T of the Osteopontin gene is associated with the susceptibility to develop gliomas and their prognosis in a Chinese cohort.
Shen Z; Chen B; Hou X; Chen P; Zhao G; Fan J
Cell Physiol Biochem; 2014; 34(4):1190-8. PubMed ID: 25277531
[TBL] [Abstract][Full Text] [Related]
3. OPN -443C>T genetic polymorphism and tumor OPN expression are associated with the risk and clinical features of papillary thyroid cancer in a Chinese cohort.
Mu G; Wang H; Cai Z; Ji H
Cell Physiol Biochem; 2013; 32(1):171-9. PubMed ID: 23867349
[TBL] [Abstract][Full Text] [Related]
4. OPN Polymorphism Is Related to the Chemotherapy Response and Prognosis in Advanced NSCLC.
Hao Y; Liu J; Wang P; Wang F; Yu Z; Li M; Chen S; Ning F
Int J Genomics; 2014; 2014():846142. PubMed ID: 25161997
[TBL] [Abstract][Full Text] [Related]
5. OPN polymorphism is associated with the susceptibility to cervical spondylotic myelopathy and its outcome after anterior cervical corpectomy and fusion.
Wu J; Wu D; Guo K; Yuan F; Ran B
Cell Physiol Biochem; 2014; 34(2):565-74. PubMed ID: 25116355
[TBL] [Abstract][Full Text] [Related]
6. Association of genetic polymorphisms in genes involved in Ara-C and dNTP metabolism pathway with chemosensitivity and prognosis of adult acute myeloid leukemia (AML).
Zhu KW; Chen P; Zhang DY; Yan H; Liu H; Cen LN; Liu YL; Cao S; Zhou G; Zeng H; Chen SP; Zhao XL; Chen XP
J Transl Med; 2018 Apr; 16(1):90. PubMed ID: 29631596
[TBL] [Abstract][Full Text] [Related]
7. OPN gene polymorphisms influence the risk of knee OA and OPN levels in synovial fluid in a Chinese population.
Jiang Y; Yao M; Liu Q; Zhou C
Arthritis Res Ther; 2013 Jan; 15(1):R3. PubMed ID: 23289928
[TBL] [Abstract][Full Text] [Related]
8. Association of polymorphisms of cytosine arabinoside-metabolizing enzyme gene with therapeutic efficacy for acute myeloid leukemia.
Xu PP; Chen BA; Feng JF; Cheng L; Xia GH; Li YF; Qian J; Ding JH; Lu ZH; Wang XM; Xu K; Schultz M
Chin Med J (Engl); 2012 Jun; 125(12):2137-43. PubMed ID: 22884143
[TBL] [Abstract][Full Text] [Related]
9. Single nucleotide polymorphisms of cytarabine metabolic genes influence clinical outcome in acute myeloid leukemia patients receiving high-dose cytarabine therapy.
Amaki J; Onizuka M; Ohmachi K; Aoyama Y; Hara R; Ichiki A; Kawai H; Sato A; Miyamoto M; Toyosaki M; Machida S; Kojima M; Shirasugi Y; Kawada H; Ogawa Y; Ando K
Int J Hematol; 2015 Jun; 101(6):543-53. PubMed ID: 25735499
[TBL] [Abstract][Full Text] [Related]
10. OPN gene polymorphism and the serum OPN levels confer the susceptibility and prognosis of ischemic stroke in Chinese patients.
Jing M; Li B; Hou X; Shoba J; Li C; Liang H; Zhang X; Liu E; Yang B; Meng X
Cell Physiol Biochem; 2013; 32(6):1798-807. PubMed ID: 24355932
[TBL] [Abstract][Full Text] [Related]
11. SAMHD1 is a biomarker for cytarabine response and a therapeutic target in acute myeloid leukemia.
Schneider C; Oellerich T; Baldauf HM; Schwarz SM; Thomas D; Flick R; Bohnenberger H; Kaderali L; Stegmann L; Cremer A; Martin M; Lohmeyer J; Michaelis M; Hornung V; Schliemann C; Berdel WE; Hartmann W; Wardelmann E; Comoglio F; Hansmann ML; Yakunin AF; Geisslinger G; Ströbel P; Ferreirós N; Serve H; Keppler OT; Cinatl J
Nat Med; 2017 Feb; 23(2):250-255. PubMed ID: 27991919
[TBL] [Abstract][Full Text] [Related]
12. STAT5 gene polymorphisms are associated with the response of acute myeloid leukemia patients to Ara-C-based chemotherapy.
Xu P; Zhou D; Ouyang J; Chen B
Leuk Lymphoma; 2016; 57(4):921-6. PubMed ID: 26384082
[TBL] [Abstract][Full Text] [Related]
13. Influence of UGT1A1 polymorphisms on the outcome of acute myeloid leukemia patients treated with cytarabine-base regimens.
Chen P; Zhu KW; Zhang DY; Yan H; Liu H; Liu YL; Cao S; Zhou G; Zeng H; Chen SP; Zhao XL; Yang J; Chen XP
J Transl Med; 2018 Jul; 16(1):197. PubMed ID: 30016963
[TBL] [Abstract][Full Text] [Related]
14. Polymorphisms at microRNA binding sites of Ara-C and anthracyclines-metabolic pathway genes are associated with outcome of acute myeloid leukemia patients.
Cao HX; Miao CF; Yan L; Tang P; Zhang LR; Sun L
J Transl Med; 2017 Nov; 15(1):235. PubMed ID: 29141648
[TBL] [Abstract][Full Text] [Related]
15. Osteopontin promoter polymorphisms at locus -443 significantly affect the metastasis and prognosis of human hepatocellular carcinoma.
Dong QZ; Zhang XF; Zhao Y; Jia HL; Zhou HJ; Dai C; Sun HJ; Qin Y; Zhang WD; Ren N; Ye QH; Qin LX
Hepatology; 2013 Mar; 57(3):1024-34. PubMed ID: 23079960
[TBL] [Abstract][Full Text] [Related]
16. The implication of osteopontin (OPN) expression and genetic polymorphisms of OPN promoter in oral carcinogenesis.
Chiu YW; Tu HF; Wang IK; Wu CH; Chang KW; Liu TY; Kao SY
Oral Oncol; 2010 Apr; 46(4):302-6. PubMed ID: 20219412
[TBL] [Abstract][Full Text] [Related]
17. The T_T genotype within the NME1 promoter single nucleotide polymorphism -835 C/T is associated with an increased risk of cytarabine induced neurotoxicity in patients with acute myeloid leukemia.
Braunagel D; Schaich M; Kramer M; Dransfeld CL; Ehninger G; Mahlknecht U
Leuk Lymphoma; 2012 May; 53(5):952-7. PubMed ID: 22035418
[TBL] [Abstract][Full Text] [Related]
18. Cytidine deaminase genetic variants influence RNA expression and cytarabine cytotoxicity in acute myeloid leukemia.
Abraham A; Varatharajan S; Abbas S; Zhang W; Shaji RV; Ahmed R; Abraham A; George B; Srivastava A; Chandy M; Mathews V; Balasubramanian P
Pharmacogenomics; 2012 Feb; 13(3):269-82. PubMed ID: 22304580
[TBL] [Abstract][Full Text] [Related]
19. GATA2 rs2335052 and GATA2 rs78245253 single-nucleotide polymorphisms in Chinese patients with acute myelocytic leukemia.
Fang F; Xu J; Kang Y; Ren H; Muyey DM; Chen X; Tan Y; Xu Z; Wang H
Int J Lab Hematol; 2021 Dec; 43(6):1491-1500. PubMed ID: 34374210
[TBL] [Abstract][Full Text] [Related]
20. Acquired expression of osteopontin selectively promotes enrichment of leukemia stem cells through AKT/mTOR/PTEN/β-catenin pathways in AML cells.
Mohammadi S; Ghaffari SH; Shaiegan M; Zarif MN; Nikbakht M; Akbari Birgani S; Alimoghadam K; Ghavamzadeh A
Life Sci; 2016 May; 152():190-8. PubMed ID: 27063991
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
